Reliable analyses of therapy-relevant genetic alterations for individualized cancer therapy
Non-invasive blood test for molecular cancer diagnostics
The hybrid capture-based NEO technology allows for the sensitive detection of clinically relevant point mutations, insertions, deletions, copy number alterations, translocations and microsatellite instability in a single sample: For reliable detection of genetic changes in routine clinical material.
All our CE-IVD-compliant products include reagents for sample processing as well as bioinformatic data analysis. This enables the customer to carry out a comprehensive molecular tumor analysis in their laboratory - from sample preparation to medical diagnosis.
Optimized processes for experimental procedures and data analysis enable fast diagnosis along with high data quality, and form the basis for a rational therapy decision.
Molecular cancer diagnostics in your laboratory
Hybrid-capture-based next generation sequencing
Media, scientific publications and conference abstracts
The founding and management team of New Oncology
Back to the top